<DOC>
	<DOCNO>NCT01887418</DOCNO>
	<brief_summary>Relative Bioavailability Safety comparison 3 formulation Testosterone Enanthate .</brief_summary>
	<brief_title>Pharmacokinetic Study Testosterone Enanthate</brief_title>
	<detailed_description>Standard Pharmacokinetic ( PK ) analyse data serum testosterone do . Cmax , Area Under Curve ( AUC ) , Cavg use comparison relative bioavailability treatment reference arm . Safety comparison base upon occurrence , severity rate treatment emergent adverse event .</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Adult male age 18 75 documented diagnosis hypogonadism Normal testosterone level Subjects clinically significant medical condition , opinion Investigator , would make subject unsuitable candidate enrollment study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Hypogonadism</keyword>
	<keyword>Testosterone enanthate</keyword>
</DOC>